ŗ«¹śĀćĪč

News

Why Valeant Pharmaceuticals Internationalā€™s new CEO may signal a shift from ā€˜disruptorā€™ to ā€˜plain vanillaā€™

Published: 28 April 2016

Ā Less than a year agoĀ Valeant Pharmaceuticals International Inc.ā€™s CEO Michael Pearson represented a disruption to big pharma by coming from outside the industry, using aggressive acquisitions and strategic business tactics to grow the company to a global giant. Ā 

Now the company has hired Joseph Papa as the new CEO, a 35-year pharmaceutical industry veteran with a history of taking a balanced approach to business. If the past few months of Pearsonā€™s tenure can be described as rocky road, Papa could help bring a new flavour to Valeant.

ā€œHeā€™s plain vanilla,ā€Ā said Robert David,Ā a professor at ŗ«¹śĀćĪčā€™s Desautels Faculty of Management.Ā 

ā€œI think plain vanilla isnā€™t such a bad thing at this time for this company. It signals stability as opposed to disruption.ā€Ā 

Read full article: , 25 April, 2016Ā 

Feedback

For more information or if you would like to report an error, please web.desautels [at] mcgill.ca (subject: Website%20News%20Comments) (contact us).

Back to top